Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent

REMEDEE Registry collaborators

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Background: When the pro-healing COMBO stent is used, a short duration of dual-antiplatelet therapy (DAPT) might be safe. However, no cases have been described of patients with short duration of DAPT after COMBO stent placement. Methods and results: We investigate clinical outcomes at 1 year after early discontinuation of DAPT in patients participating in the REMEDEE Registry. This is a prospective, multicentre, European, all-comers registry with a 1000 patients treated with COMBO stent. Target lesion failure (TLF), a composite of target vessel-myocardial infarction (tv-MI), cardiac death and target lesion revascularization, and the occurrence of stent thrombosis (ST) in relation with DAPT cessation before 30 and 180 days of follow-up is evaluated. At 30 days follow-up 48 patients were not on DAPT, at 180 days follow-up of 78 patients had no DAPT. Patients with DAPT discontinuation were older, had overall lower left ventricle ejection fraction and more frequent chronic renal failure. No TLF and especially no stent thrombosis were observed in these patients. Conclusions: Discontinuation of DAPT within 6 months after COMBO stent placement did not influence the rate of TLF up to 1-year follow-up. Large randomized trials are needed to confirm the safety of short duration of DAPT after COMBO stent placement.
Original languageEnglish
Pages (from-to)373-375
JournalCardiovasc. Revascularization Med.
Volume19
Issue number3
DOIs
Publication statusPublished - 2018
Externally publishedYes

Cite this

@article{4fcbd42a1de2428397d018f29b30046b,
title = "Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent",
abstract = "Background: When the pro-healing COMBO stent is used, a short duration of dual-antiplatelet therapy (DAPT) might be safe. However, no cases have been described of patients with short duration of DAPT after COMBO stent placement. Methods and results: We investigate clinical outcomes at 1 year after early discontinuation of DAPT in patients participating in the REMEDEE Registry. This is a prospective, multicentre, European, all-comers registry with a 1000 patients treated with COMBO stent. Target lesion failure (TLF), a composite of target vessel-myocardial infarction (tv-MI), cardiac death and target lesion revascularization, and the occurrence of stent thrombosis (ST) in relation with DAPT cessation before 30 and 180 days of follow-up is evaluated. At 30 days follow-up 48 patients were not on DAPT, at 180 days follow-up of 78 patients had no DAPT. Patients with DAPT discontinuation were older, had overall lower left ventricle ejection fraction and more frequent chronic renal failure. No TLF and especially no stent thrombosis were observed in these patients. Conclusions: Discontinuation of DAPT within 6 months after COMBO stent placement did not influence the rate of TLF up to 1-year follow-up. Large randomized trials are needed to confirm the safety of short duration of DAPT after COMBO stent placement.",
author = "{REMEDEE Registry collaborators} and Kalkman, {Deborah N.} and Pier Woudstra and Menown, {Ian B. A.} and Tijssen, {Jan G.} and Beijk, {Marcel A. M.} and {de Winter}, {Robbert J.}",
year = "2018",
doi = "10.1016/j.carrev.2017.10.005",
language = "English",
volume = "19",
pages = "373--375",
journal = "Cardiovasc. Revascularization Med.",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "3",

}

Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent. / REMEDEE Registry collaborators.

In: Cardiovasc. Revascularization Med., Vol. 19, No. 3, 2018, p. 373-375.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent

AU - REMEDEE Registry collaborators

AU - Kalkman, Deborah N.

AU - Woudstra, Pier

AU - Menown, Ian B. A.

AU - Tijssen, Jan G.

AU - Beijk, Marcel A. M.

AU - de Winter, Robbert J.

PY - 2018

Y1 - 2018

N2 - Background: When the pro-healing COMBO stent is used, a short duration of dual-antiplatelet therapy (DAPT) might be safe. However, no cases have been described of patients with short duration of DAPT after COMBO stent placement. Methods and results: We investigate clinical outcomes at 1 year after early discontinuation of DAPT in patients participating in the REMEDEE Registry. This is a prospective, multicentre, European, all-comers registry with a 1000 patients treated with COMBO stent. Target lesion failure (TLF), a composite of target vessel-myocardial infarction (tv-MI), cardiac death and target lesion revascularization, and the occurrence of stent thrombosis (ST) in relation with DAPT cessation before 30 and 180 days of follow-up is evaluated. At 30 days follow-up 48 patients were not on DAPT, at 180 days follow-up of 78 patients had no DAPT. Patients with DAPT discontinuation were older, had overall lower left ventricle ejection fraction and more frequent chronic renal failure. No TLF and especially no stent thrombosis were observed in these patients. Conclusions: Discontinuation of DAPT within 6 months after COMBO stent placement did not influence the rate of TLF up to 1-year follow-up. Large randomized trials are needed to confirm the safety of short duration of DAPT after COMBO stent placement.

AB - Background: When the pro-healing COMBO stent is used, a short duration of dual-antiplatelet therapy (DAPT) might be safe. However, no cases have been described of patients with short duration of DAPT after COMBO stent placement. Methods and results: We investigate clinical outcomes at 1 year after early discontinuation of DAPT in patients participating in the REMEDEE Registry. This is a prospective, multicentre, European, all-comers registry with a 1000 patients treated with COMBO stent. Target lesion failure (TLF), a composite of target vessel-myocardial infarction (tv-MI), cardiac death and target lesion revascularization, and the occurrence of stent thrombosis (ST) in relation with DAPT cessation before 30 and 180 days of follow-up is evaluated. At 30 days follow-up 48 patients were not on DAPT, at 180 days follow-up of 78 patients had no DAPT. Patients with DAPT discontinuation were older, had overall lower left ventricle ejection fraction and more frequent chronic renal failure. No TLF and especially no stent thrombosis were observed in these patients. Conclusions: Discontinuation of DAPT within 6 months after COMBO stent placement did not influence the rate of TLF up to 1-year follow-up. Large randomized trials are needed to confirm the safety of short duration of DAPT after COMBO stent placement.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85038816193&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29277288

U2 - 10.1016/j.carrev.2017.10.005

DO - 10.1016/j.carrev.2017.10.005

M3 - Review article

VL - 19

SP - 373

EP - 375

JO - Cardiovasc. Revascularization Med.

JF - Cardiovasc. Revascularization Med.

SN - 1553-8389

IS - 3

ER -